Navigation Links
Myocor Receives Approval for Percutaneous Trial
Date:12/5/2007

MAPLE GROVE, Minn., Dec. 5 /PRNewswire/ -- Myocor, Inc. announced that the U.S. Food and Drug Administration has granted conditional approval of the Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) feasibility study. The single-arm feasibility study will evaluate the safety and feasibility of the percutaneously implanted iCoapsys(TM) system in treating patients with mitral valve insufficiency caused by left ventricular dysfunction and coronary artery disease (CAD).

"Percutaneous valve repair is a new frontier of patient care," said Dr. Wes Pedersen, interventional director, complex valve disorders, at the Minneapolis Heart Institute. "The iCoapsys system offers patients an innovative, less invasive option for treating their functional mitral regurgitation (FMR). It is very exciting to be able to participate in the VIVID feasibility study as the principal investigator at Abbott Northwestern Hospital."

The iCoapsys device and implant procedure are based on the original, surgically implanted Coapsys(R) system. The first Coapsys device is currently being evaluated in the RESTOR-MV trial. Both devices are designed to reduce functional mitral regurgitation and reshape the left ventricle to provide a more complete reshaping therapy than traditional mitral valve repair. The development of the iCoapsys system will allow Myocor to provide physicians with both surgical and percutaneous options for their patients.

Initiation of the VIVID feasibility study is another significant milestone for Myocor, a privately held company. Since 1996, Myocor has developed a substantial portfolio of intellectual property related to mitral valve and left ventricle reshaping. "We have been very disciplined in bringing these devices through the design, manufacturing and trial processes with an eye on long-term success," said Myocor CEO, Jim Hickey. "We have been fortunate to have the experience of implanting over 120 Coapsys devices worldwide, the dedication of a talented group of employees and clinicians who believe in our therapy, and the backing of a strong investor group."

About the technology:

The Coapsys(R) and iCoapsys(TM) devices are designed to deliver the only complete, less invasive reshaping therapy for functional mitral regurgitation (FMR) and left ventricular (LV) dysfunction.

About the company:

Myocor is a clinical-trial stage medical device company. Its primary focus is on developing pioneering therapies that restore heart geometry and function. By addressing both ventricular and valvular issues, Myocor's therapies offer a complete reshaping solution for the millions of people worldwide who suffer from debilitating functional mitral regurgitation.

CONTACT:

Randolph Jennings

507.664.0482 (direct)

jennings@neuger.com


'/>"/>
SOURCE Myocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):